409 related items for PubMed ID: 22374204
1. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients.
Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD.
Ann Allergy Asthma Immunol; 2012 Mar; 108(3):195-200. PubMed ID: 22374204
[Abstract] [Full Text] [Related]
2. Respiratory Tract Deposition of HFA-Beclomethasone and HFA-Fluticasone in Asthmatic Patients.
Leach CL, Kuehl PJ, Chand R, McDonald JD.
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):127-33. PubMed ID: 26061801
[Abstract] [Full Text] [Related]
3. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers.
Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ.
Chest; 2002 Aug; 122(2):510-6. PubMed ID: 12171824
[Abstract] [Full Text] [Related]
4. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Fowler SJ, Currie GP, Lipworth BJ.
J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
[Abstract] [Full Text] [Related]
5. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[Abstract] [Full Text] [Related]
6. Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study.
Corda L, Gardenghi GG, Modina D, Montemurro LT, Novali M, Tantucci C.
Allergy Asthma Proc; 2011 Jan; 32(6):29-34. PubMed ID: 22221427
[Abstract] [Full Text] [Related]
7. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.
Edin HM, Andersen LB, Schoaf L, Scott-Wilson CA, Ho SY, Ortega HG.
Ann Allergy Asthma Immunol; 2009 Apr; 102(4):323-7. PubMed ID: 19441604
[Abstract] [Full Text] [Related]
8. [A multicenter, open-label, randomized comparison of suppressive effects on asthmatic inflammation of lower airways and improved effects on health-related QOL between HFA-BDP and fluticasone propionate].
Ohbayashi H, Adachi M, Ichinose M, Ohta K, Kokubu F, Sano Y, Tamura G, Tohda Y, Hirata K, Yasuba H.
Arerugi; 2007 Jun; 56(6):577-86. PubMed ID: 17615501
[Abstract] [Full Text] [Related]
9. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma.
Currie GP, Fowler SJ, Wilson AM, Sims EJ, Orr LC, Lipworth BJ.
Thorax; 2002 Oct; 57(10):865-8. PubMed ID: 12324672
[Abstract] [Full Text] [Related]
10. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG, Millar AB, Sykes AP.
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[Abstract] [Full Text] [Related]
11. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma.
Thongngarm T, Silkoff PE, Kossack WS, Nelson HS.
J Asthma; 2005 May; 42(4):257-63. PubMed ID: 16032934
[Abstract] [Full Text] [Related]
12. Efficacy of beclomethasone dipropionate HFA 200 microg once daily in chronic obstructive pulmonary disease and bronchial asthma.
Tatsis G, Kotsifas K, Filaditaki V, Makrantoni G, Boulia S.
J Int Med Res; 2007 May; 35(3):361-73. PubMed ID: 17593865
[Abstract] [Full Text] [Related]
13. [A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination].
Grosclaude M, Cerruti JL, Delannay B, Hérent M, Spilthooren F, Desfougères JL.
Eur Ann Allergy Clin Immunol; 2003 Nov; 35(9):356-62. PubMed ID: 14716965
[Abstract] [Full Text] [Related]
14. Usefulness of HFA-BDP for adult patients with bronchial asthma: randomized crossover study with fluticasone.
Horiguchi T, Hayashi N, Ohira D, Torigoe H, Ito T, Hirose M, Sasaki Y, Shiga M, Miyazaki J, Kondo R, Tachikawa S.
J Asthma; 2006 Sep; 43(7):509-12. PubMed ID: 16939990
[Abstract] [Full Text] [Related]
15. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.
Fowler SJ, Orr LC, Wilson AM, Sims EJ, Lipworth BJ.
Br J Clin Pharmacol; 2001 Jul; 52(1):93-5. PubMed ID: 11453895
[Abstract] [Full Text] [Related]
16. Improved delivery of inhaled steroids to the large and small airways.
Leach CL.
Respir Med; 1998 Jun; 92 Suppl A():3-8. PubMed ID: 9850357
[Abstract] [Full Text] [Related]
17. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.
Kunka R, Andrews S, Pimazzoni M, Callejas S, Ziviani L, Squassante L, Daley-Yates PT.
Respir Med; 2000 Jun; 94 Suppl B():S10-6. PubMed ID: 10919680
[Abstract] [Full Text] [Related]
18. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
Cheng YS, Fu CS, Yazzie D, Zhou Y.
J Aerosol Med; 2001 Jun; 14(2):255-66. PubMed ID: 11681657
[Abstract] [Full Text] [Related]
19. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma.
Pearlman DS, Peden D, Condemi JJ, Weinstein S, White M, Baitinger L, Scott C, Ho SY, House K, Dorinsky P.
J Asthma; 2004 Jun; 41(8):797-806. PubMed ID: 15641629
[Abstract] [Full Text] [Related]
20. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics.
Seale JP, Harrison LI.
Respir Med; 1998 Jun; 92 Suppl A():9-15. PubMed ID: 9850358
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
